Letrozole: 85 Real Stories

85 stories match letrozole. 72 of them mention hormone therapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed Central
OutcomeCancer-Free / NED
Kim, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Vision problems led to a breast cancer diagnosis (cancer-associated retinopathy)

Patient Info: Anonymized, Female

Biomarkers: Anti-recoverin and anti-alpha-enolase antibodies associated with cancer-associated retinopathy; tumor biomarkers not reported

Six years after her initial visual symptoms, vision remained stable and she remained cancer-free on surveillance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic HER2-Positive Breast Cancer With Treatment-Related Telangiectasias

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; initially ER-negative and PR-negative; metastatic disease weakly ER-positive and PR-negative; germline testing negative

Metastatic Site: left supraclavicular, mediastinal, axillary and…

Living with HER2-positive breast cancer for 9+ years since her 2014 diagnosis, including metastatic disease since 2017. She remained on reduced-dose tucatinib in 2023 while treatment-related telangiectasias improved after dose reduction and electrocautery.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast Tumor Disappears on Imaging During Treatment for Multiple Myeloma

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive, PR-positive, HER2-negative

The breast lesion showed a complete radiologic response before planned surgery, and there was no evidence of breast-cancer relapse or progression through 2022, about 5 years after diagnosis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male breast cancer in both breasts linked to Klinefelter syndrome, initially missed

Patient Info: Anonymized, Male | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Klinefelter syndrome

Metastatic Site: spine / bone

With advanced metastatic disease and an estimated prognosis of weeks or less, care focused on symptom relief under the palliative-care team.

PubMed Central
OutcomeEnd of Life / Hospice
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Breast Cancer Treatment Complicated by a Supplement–Drug Interaction

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative

Metastatic Site: bones

She resumed ribociclib with letrozole after the supplement was discontinued and the treatment-related neutropenia improved enough to restart therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast tumor with extensive tissue death (infarction)

Patient Info: Anonymized, Female

Biomarkers: Oestrogen receptor-positive; HER2 equivocal; confirmatory HER2 FISH was not performed

After 1.5 years of endocrine therapy, there was no clinical evidence of residual tumour.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic breast cancer with a blood condition that mimicked multiple myeloma

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive

Metastatic Site: bone

Her pain came under control and the metastatic breast cancer remained stable for approximately 5 years. MGUS did not progress to myeloma, and she later died from causes unrelated to cancer.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
Mary, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Mary's Survivor Story

Patient Info: Mary Richichi, female, 70+

Biomarkers: hormone receptor-positive

Mary’s breast cancer was described as under control and in remission after treatment.

Dana-Farber
OutcomeCancer-Free / NED
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV PIK3CA Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer with PIK3CA mutation and germline ATM mutation; later PD-L1 somatic change reported. HER2 not stated.

Metastatic Site: Bone, including femurs, spine, and humeri; later liver

As of October 2022, Abigail was living with Stage IV hormone-positive metastatic breast cancer after years of treatment, bone-dominant disease that later involved the liver, targeted therapies, genomic testing, and advocacy around clinical trials and patient research participation.

The Patient Story
OutcomeLiving With Cancer
Pam, who was diagnosed with Stage IV Breast CancerBreast Cancer

Teacher travels 600 miles for Dana-Farber care

Patient Info: Pam Zwemer, 50s | Stage IV

Metastatic Site: bone, stomach lining

11+ years after her original breast cancer diagnosis, she was living with Stage IV disease after bone recurrence in 2008 and spread to the stomach lining in 2011, while continuing clinical-trial care and working as a teacher.

Dana-Farber
OutcomeCare Ongoing
Stephanie, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie, Female, 60s

As of February 2022, Stephanie was living with locoregional recurrent ILC after extensive surgery and ongoing treatment with Ibrance/Femara, with recent bone, abdomen, and chest scans showing no new cancer growth and continued Femara without chemotherapy.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Granulosa Cell Tumor Recurring 17 Years After Surgery

Patient Info: Anonymized, Female, 70+

Biomarkers: Weak oestrogen sensitivity

Complete resection was not possible, but debulking relieved pressure on surrounding structures and improved her quality of life. She then continued oncology care with palliative carboplatin and paclitaxel.

PubMed Central
OutcomeCare Ongoing
Carol, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV Invasive Lobular Carcinoma: Carol's Survivor Story

Patient Info: Carol, Female, 60s | Stage IV

Metastatic Site: Bone

Carol had de novo Stage IV breast cancer with bone metastases, achieved complete remission after chemotherapy, stayed on daily Letrozole for 10 years, then returned to NED/no active disease after Kisqali and Faslodex for bone progression.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Breast cancer returned in the stomach and peritoneum after three years in remission

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: Initial breast tumor: ER 95%, PR 5%, HER2-negative, Nottingham grade 2. Metastatic peritoneal tumor: ER 80%

Metastatic Site: stomach; peritoneum

After metastatic breast cancer was confirmed in the stomach and peritoneum, she chose palliative care and inpatient hospice and died a few weeks later.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Breast cancer with sarcoidosis that mimicked metastatic disease

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Her most recent mammogram showed no recurrent breast cancer while she continued letrozole, goserelin, and six-monthly follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Occult lobular breast cancer first discovered through colon metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-negative; HER2-negative; E-cadherin-negative

Metastatic Site: colon

Her tumour marker decreased during letrozole and palbociclib treatment, but recurrent infections interrupted therapy, and she died from urosepsis 2 years after diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Recurrent Breast Cancer With a Benign-Appearing Chest-Wall Rash

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial tumor: ER-positive; PR-negative; HER2-negative.

Metastatic Site: mediastinal lymph nodes

She had recurrent chest-wall and mediastinal metastatic disease; a later rash biopsy showed dermatitis rather than another skin recurrence.

PubMed Central
OutcomeLiving With Cancer